A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

asermoaddeli Ali0 个研究点目标入组 10 人开始时间: 2023年4月30日最近更新: 2024年5月27日

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 10

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•1. Histologically or cytologically confirmed locally advanced or metastatic NSCLC.
•2. Documented EGFR ex20ins mutation demonstrated by a validated test and performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory. Institutions that don't have access to these tests should contact the sponsor for assistance.
•3. Prior treatment in the recurrent/metastatic disease setting including:
•a. A platinum-based chemotherapy regiment (or other chemotherapy regimen if platinum-based chemotherapy is contra-indicated)
•b. Any other approved standard therapy that is available to the patient, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient. In the case of a patient declining such therapy, documentation that the patient has been informed and declined should be documented in the medical record.
•c. Prior therapy with an agent approved by the local regulatory authorities for the treatment of EGFR ex20ins mutant NSCLC (Module C only). (The agent approved by the local regulatory authorities is defined as an agent approved by one of the regulatory authorities.)
•4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
•5. Age >= 18 years.
•6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

排除标准

•1. Prior treatment with an EGFR ex20ins -targeting drug (eg, including, but not limited to poziotinib, mobocertinib, amivantamab, DZD9008, BDTX-189).
•2. History of COVID-19-related pneumonitis requiring hospitalization.
•3. History of COVID-19 infection within 4 weeks prior to enrolment, or clinically significant pulmonary symptoms related to prior COVID-19 pneumonitis.
•4. Treatment with any of the following:
•a. An EGFR TKI <= 8 days or 5 x the terminal phase t1/2, whichever is longer, prior to the first dose of study drug on C1D1.
•b. Systemic anticancer treatment (excluding EGFR-TKIs as described above) within 14 days prior to the first dose of study drug on C1D1.
•c. Immunotherapy <= 28 days prior to the first dose of study drug on C1D1.
•d. Radiotherapy <= 28 days and palliative radiation <= 14 days prior to the first dose of study drug on C1D1. If irradiated, lesions must have demonstrated clear-cut progression prior to being eligible for evaluation as target lesions.
•e. Major surgery (excluding placement of vascular access) <= 28 days of the first dose of study drug on C1D1.
•5. Have any unresolved toxicity of Grade >= 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor.
•6. Have known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, treated with surgery and/or radiation, and has been stable without requiring escalating corticosteroids or anti-convulsant medications for at least four weeks prior to the first dose of study drug on C1D1.
•7. Prior therapy with CLN-081.
•8. Known hypersensitivity to CLN-081 or any drugs similar in structure or class.
•9. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, treatment-related pneumonitis, or any evidence of clinically active interstitial lung disease.
•10. Cardiac conditions as follows: Patient has a history of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment.
•11. Resting QTc > 470 msec.
•12. Patient is unable to take drugs po due to disorders or diseases that may affect GI function, including but not limited to inflammatory bowel diseases (eg, Crohn's disease, ulcerative colitis) or malabsorption syndrome, or procedures that may affect gastrointestinal function, such as gastrectomy, enterectomy, or colectomy.
•13. Have any condition or illness that, in the opinion of the Investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug.
•14. Pregnant, lactating women including if breastfeeding is interrupted or women who might be pregnant (including cases where a doctor's interview determines that the women may be pregnant); women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at within seven days prior to receiving study drug on C1D1. WOCBP and males with partners of child-bearing potential must agree to use adequate birth control throughout their participation and for six months following the last dose of study treatment (Female patients are not considered to be of childbearing potential if they are permanently sterile [hysterectomy, bilateral salpingectomy, or bilateral oophorectomy] or are post menopausal [no menses for 12 months without an alternative medic

研究者

发起方

asermoaddeli Ali

相似试验

进行中（未招募）

1 期

Phase 1/2 Study of CLN-081 in Patients with Lung Canceron-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002409-23-NLCullinan Oncology Inc.369

招募中

1 期

EUCTR2019-002409-23-ESCullinan Oncology Inc.305

招募中

不适用

Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics , Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapylung cancerNSCLC

NL-OMON56206Cullinan Oncology Inc.32

招募中

1 期

A trial to find the optimal dose of DB-OTO in infants and children with hearing loss (CHORD)Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)MedDRA version: 20.0Level: LLTClassification code: 10011874Term: Deaf Class: 10013993

CTIS2024-511342-40-00Regeneron Pharmaceuticals Inc.22

招募中

1 期

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF-V600 Mutant Solid Tumors.BRAF-V600 Mutant Solid Tumors including Melanoma, Non-small cell lung cancer, Colorectal cancer and Anaplastic thyroid carcinoma.MedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104

CTIS2022-501618-70-00C4 Therapeutics Inc.182